Key result
Novel olmesartan medoxomil synthesis enables scalable production with ~50% overall yield and high purity.
Why the study?
A simple and robust process for large-scale synthesis of olmesartan medoxomil with controlled impurity profile was needed.
Describes a robust, large-scale synthesis process for the antihypertensive drug olmesartan medoxomil with a 50% yield.
May support scalable olmesartan production; leaves open effects on clinical access, costs, or outcomes.
This document describes a simple and robust process for the synthesis of olmesartan medoxomil. This tailored process allows us to synthesize olmesartan medoxomil on a large scale with 50% overall yield. Also, our process has excellent control of the impurity profile in all the stages.
No takes yet. Share an insight, caveat, or question.
Babu et al. (2008) studied this question. A simple and robust synthesis process for olmesartan medoxomil enabled large-scale production with a 50% overall yield and excellent impurity control.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: